Company intelligence / Profile preview
Nuformix
London, United Kingdomnuformix.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Preclinical
01
Overview
Nuformix has an early-stage pipeline focused on repurposing approved drugs using novel formulations and delivery methods. Lead asset NXP002 (inhaled tranilast) targets IPF and remains in preclinical development. Other assets are at research or licensing stages. No clinical efficacy data reported yet.
- Therapeutic areas
- OncologyPulmonology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
None disclosed as of June 2025; business model focuses on future licensing/partnering at value inflection points
Beyond the preview
Go deeper on Nuformix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nuformix.